Wednesday, October 11, 2023
Cellipont Bioservices, a well-known Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy development and manufacturing, has announced a strategic partnership with Diakonos Oncology. This partnership aims to facilitate the Process Development and Current Good Manufacturing Practice (cGMP) Manufacturing of DOC1021, an autologous dendritic cell vaccine designed for the treatment of glioblastoma multiforme (GBM) and other cancer indications.
Dendritic cells have historically been underutilized in the field of immunotherapy. Diakonos' innovative approach with DOC1021 activates a patient's natural anti-viral immune response against their tumor. The remarkable results observed in the Phase 1 clinical trial, both in terms of safety and efficacy, led to the FDA granting Fast Track designation for this therapy.
Glioblastoma, the most common and most lethal primary brain tumor in adults, originates from glial cells that provide support and protection to nerve cells. Despite extensive research and development efforts, the current five-year survival rate for GBM stands at a mere 7%, with limited improvements.
Darren Head, Chairman of the Board at Cellipont Bioservices, expressed deep gratitude for being chosen as Diakonos' partner in this critical endeavor. He emphasized the company's extensive experience in cell therapy development and manufacturing, bolstered by their purpose-built Woodlands facility, as key assets that will pave the way for making this life-saving therapy accessible to numerous GBM patients.
Mike Wicks, Chief Executive Officer of Diakonos, highlighted the significance of DOC1021's personalized nature for each patient. He stressed the importance of finding a CDMO partner capable of not only facilitating the commercialization of this highly promising treatment but also exceeding the quality standards for every individual patient. Diakonos is delighted to have found such a partner in Cellipont and is enthusiastic about the potential to improve patient outcomes in GBM and other cancer indications.